Aldoxorubicin, an antineoplastic agents, is an albumin-binding prodrug of doxorubicin.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Digoxin | Digoxin may decrease the cardiotoxic activities of Aldoxorubicin. |
| Acetyldigitoxin | Acetyldigitoxin may decrease the cardiotoxic activities of Aldoxorubicin. |
| Deslanoside | Deslanoside may decrease the cardiotoxic activities of Aldoxorubicin. |
| Ouabain | Ouabain may decrease the cardiotoxic activities of Aldoxorubicin. |
| Digitoxin | Digitoxin may decrease the cardiotoxic activities of Aldoxorubicin. |
| Oleandrin | Oleandrin may decrease the cardiotoxic activities of Aldoxorubicin. |
| Cymarin | Cymarin may decrease the cardiotoxic activities of Aldoxorubicin. |
| Proscillaridin | Proscillaridin may decrease the cardiotoxic activities of Aldoxorubicin. |
| Metildigoxin | Metildigoxin may decrease the cardiotoxic activities of Aldoxorubicin. |
| Lanatoside C | Lanatoside C may decrease the cardiotoxic activities of Aldoxorubicin. |
| Gitoformate | Gitoformate may decrease the cardiotoxic activities of Aldoxorubicin. |
| Acetyldigoxin | Acetyldigoxin may decrease the cardiotoxic activities of Aldoxorubicin. |
| Peruvoside | Peruvoside may decrease the cardiotoxic activities of Aldoxorubicin. |
| Peginterferon alfa-2a | The risk or severity of cardiotoxicity can be increased when Peginterferon alfa-2a is combined with Aldoxorubicin. |
| Bevacizumab | The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Aldoxorubicin. |
| Bortezomib | The risk or severity of cardiotoxicity can be increased when Bortezomib is combined with Aldoxorubicin. |
| Cladribine | The risk or severity of cardiotoxicity can be increased when Cladribine is combined with Aldoxorubicin. |
| Carmustine | The risk or severity of cardiotoxicity can be increased when Carmustine is combined with Aldoxorubicin. |
| Amsacrine | The risk or severity of cardiotoxicity can be increased when Amsacrine is combined with Aldoxorubicin. |
| Bleomycin | The risk or severity of cardiotoxicity can be increased when Bleomycin is combined with Aldoxorubicin. |
| Mitomycin | The risk or severity of cardiotoxicity can be increased when Mitomycin is combined with Aldoxorubicin. |
| Vindesine | The risk or severity of cardiotoxicity can be increased when Vindesine is combined with Aldoxorubicin. |
| Vinorelbine | The risk or severity of cardiotoxicity can be increased when Vinorelbine is combined with Aldoxorubicin. |
| Teniposide | The risk or severity of cardiotoxicity can be increased when Teniposide is combined with Aldoxorubicin. |
| Epirubicin | The risk or severity of cardiotoxicity can be increased when Epirubicin is combined with Aldoxorubicin. |
| Cisplatin | The risk or severity of cardiotoxicity can be increased when Cisplatin is combined with Aldoxorubicin. |
| Cyclophosphamide | The risk or severity of cardiotoxicity can be increased when Cyclophosphamide is combined with Aldoxorubicin. |
| Vincristine | The risk or severity of cardiotoxicity can be increased when Vincristine is combined with Aldoxorubicin. |
| Fluorouracil | The risk or severity of cardiotoxicity can be increased when Fluorouracil is combined with Aldoxorubicin. |
| Pentostatin | The risk or severity of cardiotoxicity can be increased when Pentostatin is combined with Aldoxorubicin. |
| Methotrexate | The risk or severity of cardiotoxicity can be increased when Methotrexate is combined with Aldoxorubicin. |
| Vinblastine | The risk or severity of cardiotoxicity can be increased when Vinblastine is combined with Aldoxorubicin. |
| Imatinib | The risk or severity of cardiotoxicity can be increased when Imatinib is combined with Aldoxorubicin. |
| Tamoxifen | The risk or severity of cardiotoxicity can be increased when Tamoxifen is combined with Aldoxorubicin. |
| Daunorubicin | The risk or severity of cardiotoxicity can be increased when Daunorubicin is combined with Aldoxorubicin. |
| Tretinoin | The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Aldoxorubicin. |
| Etoposide | The risk or severity of cardiotoxicity can be increased when Etoposide is combined with Aldoxorubicin. |
| Mechlorethamine | The risk or severity of cardiotoxicity can be increased when Mechlorethamine is combined with Aldoxorubicin. |
| Doxorubicin | The risk or severity of cardiotoxicity can be increased when Doxorubicin is combined with Aldoxorubicin. |
| Busulfan | The risk or severity of cardiotoxicity can be increased when Busulfan is combined with Aldoxorubicin. |
| Thalidomide | The risk or severity of cardiotoxicity can be increased when Thalidomide is combined with Aldoxorubicin. |
| Fludarabine | The risk or severity of cardiotoxicity can be increased when Fludarabine is combined with Aldoxorubicin. |
| Capecitabine | The risk or severity of cardiotoxicity can be increased when Capecitabine is combined with Aldoxorubicin. |
| Arsenic trioxide | The risk or severity of cardiotoxicity can be increased when Arsenic trioxide is combined with Aldoxorubicin. |
| Idarubicin | The risk or severity of cardiotoxicity can be increased when Idarubicin is combined with Aldoxorubicin. |
| Ifosfamide | The risk or severity of cardiotoxicity can be increased when Ifosfamide is combined with Aldoxorubicin. |
| Mitoxantrone | The risk or severity of cardiotoxicity can be increased when Mitoxantrone is combined with Aldoxorubicin. |
| Anastrozole | The risk or severity of cardiotoxicity can be increased when Anastrozole is combined with Aldoxorubicin. |
| Paclitaxel | The risk or severity of cardiotoxicity can be increased when Paclitaxel is combined with Aldoxorubicin. |
| Docetaxel | The risk or severity of cardiotoxicity can be increased when Docetaxel is combined with Aldoxorubicin. |
| Paclitaxel trevatide | The risk or severity of cardiotoxicity can be increased when Aldoxorubicin is combined with Paclitaxel trevatide. |
| Cabazitaxel | The risk or severity of cardiotoxicity can be increased when Aldoxorubicin is combined with Cabazitaxel. |
| Paclitaxel poliglumex | The risk or severity of cardiotoxicity can be increased when Aldoxorubicin is combined with Paclitaxel poliglumex. |
| Pertuzumab | The risk or severity of cardiotoxicity can be increased when Aldoxorubicin is combined with Pertuzumab. |
| Trastuzumab | The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Aldoxorubicin. |
| Margetuximab | The risk or severity of cardiotoxicity can be increased when Margetuximab is combined with Aldoxorubicin. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Aldoxorubicin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Aldoxorubicin. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Aldoxorubicin. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Aldoxorubicin. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Quinisocaine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Aldoxorubicin. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Aldoxorubicin is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Aldoxorubicin is combined with Etrasimod. |